Clopidogrel Resistance in Ischemic Stroke Patients

Area of Science:

• Cardiology
• Pharmacogenomics
• Neurology

Background:

• Stroke is a leading global cause of death, with antiplatelet drugs like clopidogrel crucial for prevention post-stroke.
• Patient response to clopidogrel varies, necessitating an understanding of clopidogrel resistance (CR).

Purpose of the Study:

• To review clopidogrel resistance in stroke patients, including its risk factors and identification methods.
• To highlight the impact of genetic polymorphisms, particularly CYP2C19, on clopidogrel efficacy.

Main Methods:

• Review of literature on clopidogrel resistance, genetic factors (CYP2C19 *2, *3), and other influencing elements.
• Discussion of diagnostic methods for assessing platelet reactivity and CR.
• Identification of alternative antiplatelet strategies.

Main Results:

• CYP2C19 genetic variants (*2, *3) are prevalent and significantly impact clopidogrel response, with carriers showing poorer outcomes.
• Factors like drug interactions (PPIs), age, sex, and comorbidities also contribute to CR.
• Platelet reactivity testing (e.g., VASP, Verify Now) can identify CR.

Conclusions:

• CYP2C19 genotyping is vital for predicting clopidogrel response in stroke patients.
• Alternative antiplatelet agents like ticagrelor may be more effective in patients with CR.
• Concurrent use of clopidogrel and proton pump inhibitors should be carefully considered.